By Joseph Harvey
January 5, 2017
Bayer Animal Health has completed its acquisition of Boehringer Ingelheim Vetmedica's Cydectin endectocide products in the US.
The deal allows Bayer to enter the US market for bovine and ovine endectocides. This move is particularly synergistic for Bayer, as it is currently the leader in the livestock insecticides sector. Financial terms of the deal were not revealed.
The acquisition gives Bayer ownership of Cydectin Pour-On, Cydectin Injectable and Cydectin Oral Drench. These endectocides have the active ingredient moxidectin and offer persistent killing of internal parasites such as Ostertagia ostertagi (brown stomach worm). The products also control external parasites including lice, grubs and psoroptic mange mites on beef and dairy cattle.
The deal for the Cydectin assets was first announced in December and was pending the closure of Boehringer's animal health merger with Merial, which also occurred this week. Reprinted with permission of Animal Pharm News